ROBERIA DE PONTES

Mrs. ROBERIA DE PONTES

Internal Medicine Postgraduate Program, Faculty of Medicine and Cytometry Service, Institute of Paediatrics and Puericultura Martagão Gesteira (IPPMG), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2017 in Leukemia
Verified
Journal Article
Open access
JFJuan Flores-Montero
Juan Flores-Montero
LSL Sanoja-Flores
L Sanoja-Flores
BPB Paiva
B Paiva
NPN Puig
N Puig
OGO García-Sánchez
O García-Sánchez
AOAlberto Orfao
Alberto Orfao
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.

19 November 2018 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
LSL. Sanoja-Flores
L. Sanoja-Flores
JFJuan Flores-Montero
Juan Flores-Montero
JGJuan-José Garcés
Juan-José Garcés
BPB. Paiva
B. Paiva
NPN. Puig
N. Puig
AOAlberto Orfao
Alberto Orfao
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p <0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p <0.0001) and a shorter survival in MM patients with active disease requiring treatment (p ≤ 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.

12 December 2019 in Blood
Verified
Journal Article
Open access
PDF file
LFLuzalba Sanoja Flores
Luzalba Sanoja Flores
JFJuan Flores-Montero
Juan Flores-Montero
NPNoemi Puig
Noemi Puig
TCTeresa Contreras-Sanfeliciano
Teresa Contreras-Sanfeliciano
ROBERIA DE PONTESROBERIA DE PONTES
ROBERIA DE PONTES
AOAlberto Orfao
Alberto Orfao

3 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ROBERIA DE PONTESROBERIA DE PONTES
ROBERIA DE PONTES
JFJuan Flores-Montero
Juan Flores-Montero
LFLuzalba Sanoja Flores
Luzalba Sanoja Flores
Noemí PuigNoemí Puig
Noemí Puig
RMRoberto J. Pessoa de Magalhães
Roberto J. Pessoa de Magalhães
AOAlberto Orfao
Alberto Orfao
B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19− nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.

21 February 2017 in Hematology
Verified
Journal Article
Closed access
ROBERIA DE PONTESROBERIA DE PONTES
ROBERIA DE PONTES
ECElaine Sobral da Costa
Elaine Sobral da Costa
PSPatricia Fernanda Rosa de Siqueira
Patricia Fernanda Rosa de Siqueira
JMJussara F. F. Medeiros
Jussara F. F. Medeiros
ASAndréa Soares
Andréa Soares
MFMarcos K. Fleury
Marcos K. Fleury
Objectives: Cholecystitis is one of the complications of symptomatic cholelithiasis responsible for high levels of morbidity of sickle cell disease (SCD) patients. Here, we investigated the possible protective role of single gene deletions of α-thalassaemia in the occurrence of cholelithiasis and cholecystitis in SCD patients, as well as the cholecystectomy requirements. Methods: The α-globin genotype was determined in 83 SCD patients using the multiplex-polymerase chain reaction and compared with clinical events. Results: Overall, in 23% of patients, -α3.7 deletion was found. α-Thalassaemia concomitant to SCD was an independent protective factor to cholecystitis (OR = 0.07; 95% CI: 0.01–0.66; p = 0.020) and cholecystectomy requirement (OR = 0.14; 95% CI: 0.03–0.60; p = 0.008). The risk of cholelithiasis was not affected by the α-thalassaemia concomitance. Conclusions: To the best our knowledge, our study is the first to show the protective effect of α-thalassaemia on cholecystitis and cholecystectomy requirements in SCD, which may be due to an improved splenic function.

1 September 2025 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
KMKarina Mescouto De Melo
Karina Mescouto De Melo
ADAnna C.S. Dias
Anna C.S. Dias
ROBERIA DE PONTESROBERIA DE PONTES
ROBERIA DE PONTES
CVCláudia F.C. Valente
Cláudia F.C. Valente
FTFabíola S. Tavares
Fabíola S. Tavares
RCRicardo Camargo
Ricardo Camargo
The diagnosis of chronic granulomatous disease (CGD), a congenital immunodeficiency affecting phagocyte function, remains a challenge for patients in Latin America. It is well established that dihydrorhodamine (DHR) flow cytometry is the most commonly used screening assay; however, few pediatric immunology centers in Brazil perform this test. This study reports data from a routine diagnostic workup for CGD conducted at a Brazilian children’s hospital. A three-year prospective study was performed, enrolling children with clinical features suggestive of immunodeficiency who were screened using DHR. Sanger sequencing of the NCF1 (neutrophil cytosolic factor 1) and CYBB (cytochrome b-245, beta chain) genes was conducted in children with two consecutive abnormal DHR results. A total of 255 patients—62% males—with a median age of 3.2 years (range: 1 month–17.8 years) were evaluated. Six patients (2.4%) had abnormal DHR tests, and four of them (1.6%) received a definitive diagnosis of CGD. Most children presented with pneumonia and/or abscesses during the first year of life as the clinical manifestation of CGD. Two of the four diagnosed patients were receiving continuous antibiotics and two underwent transplantation. Pathogenic variants were identified in NCF1 (three cases) and CYBB (one case). The hospital-based diagnostic workup for CGD identified approximately one new case per 60 tested patients, indicating a high frequency of the disease in the study population. This approach may represent a valuable strategy for identifying new pediatric CGD cases in resource-limited settings.